Researchers from University of Bristol and affiliated organizations performed studies to identify new risk factors that would predict future cardiovascular events after an incident stroke.
Heart failure with preserved ejection fraction (HFpEF) is associated with hypertension and metabolic disorders and remains one of the main challenges for cardiovascular risk management. Researchers from the University of Cincinnati, Duke University School of Medicine, Remd Biotherapeutics Inc. and collaborators described the use of targeted inhibition of glucagon signaling as a potential strategy to rescue the pathological features of HFpEF.
Opna Bio AG has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of arrhythmogenic right ventricular cardiomyopathy, cancer, Holt-Oram syndrome, neurofibromatosis type 2, polycystic kidney disease and Alzheimer’s disease.
Thyroid hormones are involved in growth, development and metabolism processes. The thyroid hormone receptor β (THRβ) isoform, mainly expressed in the liver, is responsible for the reduction of cholesterol levels and thus is considered a therapeutic target for the treatment of dyslipidemia, obesity and related disorders.
Angiotensin II is a potent vasopressor hormone and a primary regulator of aldosterone secretion involved in controlling blood pressure and volume in the cardiovascular system. Antagonists of the angiotensin II type 1 (AT1) receptor are used for the management of hypertension with proven efficacy.
With a move into Lilly Gateway Labs in Boston’s Seaport District, privately held Tevard Biosciences Inc. is ramping up development of its transfer RNA (tRNA)-based therapies to cure everything from Dravet syndrome and other neurological conditions to cardiology indications and muscular dystrophies.
Esculetin, also known as 6,7-dihydroxycoumarin, is a coumarin-derived phytochemical that has shown effects against ischemic stroke. Additionally, chemokine-like factor 1 (CKLF1) has been revealed in previous findings to be a target for stroke when using coumarin-derived compounds. The effects of esculetin and the potential involvement of CKLF1 were tested in photothrombotic stroke in mice.
Researchers from Edgewise Therapeutics Inc. presented preclinical data for the cardiac sarcomere modulator, EDG-7500, which is being developed for the treatment of hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction.
Researchers from the University of Pennsylvania have successfully inhibited vasohibin enzymes (VASH) with SVC-01 and SVC-02 in the ZSF1 obese rat model of heart failure with preserved ejection fraction (HFpEF).
RSS
